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Abstract
 Introduction—Hormonal contraception with DMPA may increase HIV acquisition risk, but 
observational human studies are inconclusive, and animal models can help investigate this risk. 
Here we test the impact of a low DMPA dose, designed to resemble human contraceptive use, on 
SHIV acquisition risk in pigtail macaques (Macaca nemestrina).
 Methods—Macaques metabolize DMPA faster than humans. We previously identified a per-
weight DMPA dose and administration frequency that achieves long-lasting suppression of 
ovulation in macaques. Eight macaques were given 1.5 mg/kg DMPA monthly, while eleven were 
untreated controls. For comparison, women receive 150 mg (approximately 2 mg/kg) every 3 
months. We exposed monkeys to 20 sub-optimal SHIV challenges, designed to slowly infect half 
of controls and allow increased infection in the DMPA group.
 Results—It took a median 5.5 viral challenges to infect DMPA-treated macaques, and 9 
challenges for controls (p=0.27; exact conditional logistic regression). The exact odds ratio was 
2.2 (CI 0.6 – 8.3). Ovulation was suppressed, and the vaginal epithelium was thinned after DMPA-
treatment in all animals (mean 30 and 219 micrometers in DMPA-treated and control macaques, 
respectively, p=0.03, t-test using the Satterthwaite degrees-of-freedom approximation).
 Conclusions—SHIV infections in DMPA treated macaques were 2.2 times those of controls, 
but this was not statistically significant. The result is remarkably similar to studies of human 
DMPA use, which have shown HIV risk increases of a similar magnitude and of variable 
significance. Taken together with previous studies of higher DMPA doses in macaques, the results 
suggest a dose-dependent effect of DMPA on SIV or SHIV acquisition.
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The injectable hormonal contraceptive DMPA (depot medroxyprogesterone acetate, brand 
name Depo-Provera® [Pfizer, New York, NY]) has been associated with increased HIV 
acquisition risk in observational studies (recently reviewed 1-4), although the statistical 
significance and magnitude of the risk increase remains under discussion. Ongoing research 
focuses on determining underlying biological mechanisms5, characterizing potentially safer 
alternatives such as Net-en 6, and identifying other risk factors like young age and co-
STIs 7,8. In addition, a planned randomized clinical trial may clarify the issue9, but results 
are not expected for several years. In the meantime, animal model studies can uniquely and 
relatively quickly contribute to the comprehensive scientific evaluation of DMPA.
Early macaque model studies clearly demonstrated increased infection risk during high-dose 
injectable DMPA use, or other routes of high-dose progestin administration10,11. These 
studies provided proof-of-concept data for the potential of progestins to increase risk, and 
further work allowed identification of associated biological mechanisms contributing to 
increased HIV transmission, such as the thinning of vaginal epithelial walls10,11. Early 
studies done with high progestin doses, e.g., 200 mg progestin implants, were reported to 
enhance vaginal SIV transmission to 7.7 fold in rhesus macaques10. Later studies frequently 
used single, 30 mg DMPA intra-muscular doses to facilitate vaginal SIV infection for 
biomedical research studies (e.g., recently used in our research group12, and reviewed by 
Veazey et al 13), although the associated risk increase with this dose (4.3mg/kg in an average 
weight (7kg) macaque) has not been quantitated to our knowledge. Taken together, the 
studies contributed greatly to HIV risk factor and contraceptive research, but also earned the 
criticism that high doses of progestins may not be comparable to human contraceptive use 
and may overestimate infection risk.
Here we asked the question whether a DMPA dose modeled after human Depo-Provera® use 
is associated with increased vaginal infection risk in a pigtail macaque model of SHIV 
infection. The goal of the research is to develop a realistic animal model that would allow 
further investigation of current research questions around safe use of contraception for 
women at risk of HIV infection.
In women, the standard contraceptive dose of 150 mg is given every 3 months, and equates 
to 2 mg/kg in an average weight woman (75kg) living in the United States14. Macaques, 
however, metabolize DMPA faster than women15. In particular, after intramuscular DMPA 
injection of comparable doses in macaques, MPA appearance in blood peaks faster and at 
higher levels than in humans, but it also declines faster and disappears within one month, 
while it remains detectable for much longer in humans15. In earlier work by us and our 
colleagues16-18, various DMPA doses were tested in pigtail macaques (1, 3, 15, 30 mg per 
macaque, and 0.5, 1.5, and 2.5 mg/kg of body weight). We determined resulting blood MPA 
levels over time, and their effectiveness in suppressing ovulation, their ability to induce 
thinning of the vaginal epithelium, and their effects on other putative HIV susceptibility 
factors. We showed that a low, monthly DMPA dose of 1.5 mg/kg can achieve suppression 
of ovulation over two months 18, while it also achieves constantly detectable MPA levels, 
and is associated with significant vaginal epithelial thinning. Other slightly lower or higher 
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doses were also associated with changes in these parameters16-18. In summary, we selected 
1.5 kg/mg DMPA given monthly for our current study. The study was designed to determine 
associated SHIV risk in a model of repeated, low-dose, vaginal SHIV exposure19, given to 
realistically mimic the human situation where not every HIV exposure leads to infection.
 Methods
 Animals; Ethics statement
We purchased twelve female pigtail macaques (Macaca nemestrina), aged 5 to 15 years 
(Supplemental Table 1), and weighing 5 – 8 kg. They were housed at CDC in an AAALAC-
accredited facility with veterinary oversight. Housing conditions, enrichment, and all 
experimental procedures were reviewed and approved by the CDC IACUC (Institutional 
Animal Care and Use Committee). All recommendations of the Guide for the Care and Use 
of Laboratory Animals20 were followed, including those for enrichment and minimization of 
suffering. All sample collections were performed under anesthesia with Ketamine, often 
together with Telazol.
 Study Design
Eight macaques were placed in a DMPA-treated group, four served as real-time untreated 
controls. Data from seven additional untreated macaques were included as historical 
controls21. Study phases were: I: Daily visual menstrual cycle observation for up to four 
weeks; II: Baseline sample collection weekly for 3 weeks (blood and vaginal swab 
collection); III: Commencement of DMPA injections (see below) two weeks prior to the first 
virus administration, then repeated virus and DMPA administrations (see below) with 
continuing weekly blood draws. Phase III ended when an animal was infected, or continued 
until 20 virus challenges were completed. IV. Continued DMPA injections and monitoring of 
infections for up to 12 weeks (weekly blood draws, vaginal swabs, biopsy collection).
 Virus; Repeat-Low dose model; Infection determination
To determine SHIV acquisition risk, we administered 20 weekly vaginal SHIVSF162P322 
exposures at 10 TCID50, lower than our standard virus dose and designed to cause infection 
in only half of control macaques, thus allowing detection of increased infection in the 
DMPA group21. The virus stock was produced at CDC, using an inoculation stock obtained 
through the NIH AIDS Reagent program (Germantown, MD). As previously described21, an 
in-house real-time PCR assay was used to determine infection when blood plasma levels 
reached at least 50 copies/ mL in two consecutive blood samples. Infection or lack thereof 
was confirmed with an in-house assay for proviral DNA integration in PBMCs, and with 
detection of anti-HIV 1/2 antibodies as described21.
 DMPA administration; menstrual cycle determination
We purchased Depo-Provera® from Pfizer (New York, NY) and injected suspensions of 1.5 
mg/kg DMPA into the gluteal muscle every 28 days as described 18. Menstrual cycling was 
monitored by visual observation and plasma progesterone18. Visual observations were 
recorded on every weekday throughout, and included menstrual blood and perineal 
tumescence (“sex skin swelling”, documented in 23). Plasma progesterone and MPA were 
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measured at the Wisconsin National Primate Research Center, as previously described 18. 
Vaginal pH was recorded after infection or at study end before biopsy collection, and did not 
differ in study groups (supplemental Table 1, and data not shown).
 Epithelial analyses
We obtained biopsy punches from three separate vaginal sites from each animal and 
measured the thicknesses of the superficial non-nucleated epithelial layer and the combined 
underlying nucleated epithelial cell layers, as previously described in detail 18. In brief, after 
H&E staining of sectioned, slide-mounted tissues, we used the ScanScope imaging system 
(Aperio, Vista, CA) and HALO image analysis software's epithelial thickness algorithm 
(Indica Labs, Corrales, NM) to measure epithelial thickness at 50 micron intervals along the 
entire length of appropriately oriented tissue sections from the three punches. A board-
certified veterinary pathologist delineated the nucleated and non-nucleated cell layers, as 
previously described18,24.
 Statistics
GraphPad Prism software version 5.03 (San Diego, CA) was used to construct Kaplan-Meier 
survival curves and other graphs, to calculate descriptive statistics, and to perform 
parametric and non-parametric statistical tests to assess treatment group differences. We 
performed exact conditional logistic regression in SAS version 9.3 software to test for group 
differences in risk for infection using repeat-low dose infection data 25. For survival 
analyses, uninfected macaques were right censored at the maximal exposure number (20 
exposures).
 Results
 Infection risk during DMPA treatment
The study question was whether DMPA treatment at a dose of 1.5 mg/kg increases risk of 
vaginal SHIV infection. We used a model of repeated virus exposures at very low, sub-
infectious virus dose (10 TCID50 of SHIVSF162P3) and hypothesized that untreated controls 
would be infected after many exposures or remain uninfected, while DMPA-treated animals 
would experience rapid infection. Of eight female, DMPA-treated pigtail macaques five 
were infected within the first six challenges, two after 19 challenges, and the eighth macaque 
remained uninfected after 20 virus challenges. Overall, it took a median 5.5 challenges to 
infect DMPA-treated macaques. Two of the four real-time control animals became infected, 
as did four of seven control animals that had previously been subjected to the same SHIV 
exposure regimen21. In all, a median of nine viral challenges were required for infection of 
controls. The difference in challenges to infection were not statistically significant (p=0.18, 
log-rank test). These results are graphically displayed in Fig. 1A with Kaplan-Meier survival 
curves depicting how many animals remained uninfected after each challenge. We opted to 
display the number of virus challenges rather than menstrual cycles19 during challenges 
because DMPA abrogates cycling (see below). SHIV infection in DMPA-treated macaques 
were 2.2 (95% CI 0.6 – 8.3) those in control animals, though this was not statistically 
significant (p=0.27, exact conditional logistic regression). Seven of eight DMPA-treated 
macaques became infected, compared to six of 11 controls (Fig. 1B, p=0.18, Fisher's exact 
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test). Thus, DMPA treatment at 1.5 mg/kg did not significantly increase SHIV infection risk 
whether analyzed at the exposure or individual level.
The course of resulting SHIV infections is described in Fig. 2. Fig. 2A shows plasma viral 
RNA levels in the two control animals infected in real time. Infection data of historic control 
infections were previously published with similar results21. In Fig. 2B, the infection course 
of seven DMPA-treated, infected macaques is shown while they continued to receive DMPA 
for at least 12 weeks post infection. The uninfected, treated animal BB0499 is also shown. 
At peak viremia, the median log10 transformed values were 7.0 and 6.2 RNA copies per 
milliliter of plasma in DMPA or untreated animals, respectively (Fig. 2C). This was not 
statistically significantly different (p=0.94, Mann-Whitney U test). A comparison of 
treatment groups for total viremia over the course of 15 weeks post infection by assessing 
differences in the distributions of area under the viral load curves (Fig. 2D) was not 
statistically significant (p=0.83, Mann-Whitney U test).
 DMPA treatment at 1.5 mg/kg suppressed menstrual cycling and ovulation
DMPA prevents pregnancy by suppressing ovulation and menstrual cycling, among other 
mechanisms that contribute to preventing fertilization, such as changes in mucus properties. 
We examined the effect of monthly 1.5 mg/kg DMPA injections on menstrual cycling. Fig. 
3A and B show cycling information for all twelve macaques throughout all of their study 
phases (baseline, virus challenge, and post infection), for up to 320 study days. At study start 
and before treatment, all but two animals had plasma progesterone peaks recorded, a sign of 
recent ovulation as progesterone is produced by the corpus luteum after ovulation. The 
remaining two animals BB0539 and BB403 (Fig. 3A) likely had no progesterone peak 
recorded because we only took blood samples for three weeks. Nonetheless, the two animals 
had evidence of active menstrual cycles at study start based on the swelling of their “sex 
skin” (perineal tumescence), i.e., the color and size changes of the genital area associated 
with rising estrogen during menstrual cycling in this species (previously documented in 23). 
When DMPA injections started, all eight treated animals had cessation of progesterone 
fluctuations, indicating lack of cycling. In contrast, control animals continued to cycle (Fig. 
3B). Thus, the DMPA treatments were effective in suppressing ovulation, as we had 
previously shown in three similarly treated animals over two months18. As expected, 
suppression occurred shortly after MPA levels became measureable in plasma (Fig. 4A). The 
figure shows the relationship of endogenous progesterone (left y-axis) and plasma MPA 
(right y-axis) for each treated animal. The uninfected, DMPA-treated macaque BB0499 had 
measurable MPA levels of comparable magnitude as other animals (Fig. 4B), indicating that 
drug absorption following intramuscular DMPA injection was normal.
 DMPA treatment at 1.5 mg/kg caused vaginal epithelial thinning
DMPA treatment may increase vaginal HIV infection risk by thinning the vaginal 
epithelium10, among other mechanisms, thus limiting its barrier function and permitting 
HIV easier access to underlying target cells. We measured epithelial thinning in biopsy 
tissues taken shortly after infection in each animal, or at the end of vaginal virus challenges 
in uninfected animals. Fig. 5 shows that all DMPA-treated macaques had extensive thinning 
of the epithelium. Fig. 5A displays examples of the vaginal epithelial architecture. The top 
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images are from an untreated animal (BB0540). The top left image illustrates the nucleated 
and non-nucleated epithelial layers, and the underlying stroma. The top right image shows 
the same tissue after manual delineation of the epithelial layers and automated thickness 
measurements at 50 micron intervals. The bottom images are from DMPA-treated animals, 
and show complete loss of the non-nucleated layer, as well as marked thinning of the 
nucleated layers, leaving the underlying stroma close to the vaginal lumen. For the four 
control animals, mean total epithelial thickness (all epithelial layers combined) was 219 
(Standard Deviation 97.6) micrometers, and differences between controls were likely due to 
the random time points within the menstrual cycle at time of biopsy (Fig. 5B). In contrast, 
the epithelium of DMPA-treated animals had a mean thickness of 30 (Standard Deviation 
8.4) micrometers, and none of the animals had the superficial non-nucleated cell layer, as 
was previously reported for this and other DMPA doses16-18. The difference in thicknesses 
between study groups was statistically significant (p=0.03, Satterthwaite t-test for groups 
with unequal variances).
 Discussion
In summary, we here show that SHIV infections in macaques treated with a human-
equivalent dose of DMPA were 2.2-times those of untreated controls, though this difference 
was not statistically significant. This finding was obtained despite robust suppression of 
ovulation and induction of putative HIV susceptibility factors such as vaginal thinning, and 
likely also increases in vaginal pH18, as we have previously shown in different pigtail 
macaques treated with this DMPA dose 18.
Our goal was to develop a realistic animal model for further HIV prevention research such 
as PrEP regimen testing or risk comparisons with other contraceptive products. We expected 
to find a risk increase associated with DMPA injections, based on earlier work in rhesus 
macaques reporting that progesterone implants enhanced SIV transmission to 7.7-fold over 
placebo-treated macaques10. The ubiquitous use of DMPA in macaque models to facilitate 
otherwise uncertain vaginal virus transmission also contributed to our expectations 
(reviewed by Veazey 13, and also recently employed by our research team12). However, we 
did not observe a statistically significant treatment group difference, and we conclude that 
this is likely a result of the comparatively low DMPA dose employed here, which was 
modeled as a human-equivalent dose.
The non-significant odds ratio of 2.2 was nonetheless perhaps not surprising, as it was in the 
range of the most recent data from human observational studies. In meta-analyses of 
epidemiologic evidence concerning DMPA and HIV risk, Polis et al described “persisting 
uncertainty whether DMPA increases risk of HIV acquisition”3, with some studies finding 
no association, others between 1.5 and 2.2 times the risk 2. Similarly, Ralph et al., recently 
determined a pooled HR of 1.40 (95% CI 1·16-1·69) in the general population, with 
heterogeneity between studies, and higher among women at high risk of HIV infection 1, 
while Morrison et al determined a HR of 1.5 relative to no hormonal contraception 4. 
Observational studies in humans may under- or overestimate risk increases during DMPA 
use due to study confounding by potentially different sexual behavior or condom use with 
and without DMPA contraception. Future results from randomized clinical trials with 
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expected minimized confounding conditions will further clarify how closely the macaque 
data resemble the human situation. In all, our results are in the range of current data on 
human DMPA use with regards to magnitude and significance of findings. Although animal 
model data are often best understood as proof-of-concept studies, and do not necessarily 
allow quantitative comparisons to human data, we can conclude that use of a human-like 
DMPA dose resulted in a human-like outcome with regards to SHIV infection risk in this 
model.
Two- to three-fold risk differences can be difficult to detect in animal models due to 
limitations in animal group sizes and resulting limited statistical power (recently reviewed 
in 26). Prior experiences with this macaque model allowed us to consider potential group 
sizes and power to detect modest risk differences. We had previously demonstrated a relative 
risk of 2.5 (95% CI 1.1 – 5.6) for vaginal SHIV infection associated with pre-existing co-
infection with STIs over STI-naïve animals, using a similar model of repeated vaginal SHIV 
exposures at sub-infectious virus doses21. Based on sample size calculations, we estimated 
the current study design allowed 80% power to detect a true odds ratio of approximately 2.5 
with a 2-sided significance level of 0.05 if eight DMPA-treated animals readily became 
infected, and if the four real-time controls behaved like the seven historic controls. However, 
we did not observe early infections in all animals, as one animal did not become infected 
during DMPA treatment, and two additional animals had infections after 19 virus exposures. 
Thus, there was insufficient power to conclude statistically significant differences for an 
observed odds ratio <2.5.
The selection of a 1.5 mg/kg DMPA dose as similar to human Depo-Provera® use has 
previously been justified and discussed 18. It was based on a combination of factors such as 
effectiveness of ovulation suppression over two months, MPA levels, vaginal thinning, and 
vaginal pH changes in a group of three animals. We here obtained similar results for changes 
in some of these factors, in a larger group of animals, and over a longer period of time. 
Changes in pH were not measured throughout because it requires vaginal swabbing, thus, 
this was intentionally not undertaken in this trial so the vaginal mucosa was not disturbed 
manually before virus inoculations. It is possible and even likely that higher or lower DMPA 
doses might result in different infection outcomes. Of note, and consistent with our results, 
an even lower dose of 3 mg DMPA per animal did not decrease efficacy of Truvada for HIV 
prevention in a similar pigtail macaque model16,17. This suggests that the lower 3 mg DMPA 
dose also did not increase SHIV infection risk, although risk was not directly evaluated at 
this dose16,17.
Taken together with previous data from DMPA use in macaques, our results suggest a dose 
dependency of increased vaginal SIV/ SHIV infection risk in macaques. It remains unclear 
whether a similar DMPA/ HIV risk dose-dependency exists in women. Women receive a 
Depo-Provera® dose of 150 mg, regardless of their weight, age, or reproductive history. This 
dose peaks and then declines over the course of three months, when the next injection is due. 
MPA levels thus vary over the three months of contraceptive efficacy in each woman. There 
is therefore no one DMPA dose that perfectly models all possible human scenarios. Our 
results are somewhat reassuring regarding HIV infection risk, since we considered the dose 
as likely equivalent to an average human dose, with the caveats of animal model data as 
Butler et al. Page 7













discussed above. At the same time, one could hypothesize that women with low body mass 
who receive the standard 150 mg MPA dose (e.g., small women with low body weight) 
could have a relatively higher HIV infection risk during Depo-Provera® use than heavier 
women. If confirmed by human data, this could be avoided by administering DMPA on a 
strict per-weight basis to women.
Although we could not demonstrate a statistically significant risk increase associated with 
1.5 mg/kg DMPA, we still observed increases in putative HIV risk factors such as vaginal 
thinning and, in our previous work, pH increases that likely reflect changes in the vaginal 
microbiome18. We have previously demonstrated a relationship between vaginal epithelial 
thinning and SHIV infection risk in this model 24, although vaginal thinning occurs to a 
lesser degree in women, if at all 27. In humans, the link between several biological changes 
and HIV infection risk during DMPA use remains under active study and discussion 
(reviewed by 5). Furthermore, our data do not exclude the possibility that there is a moderate 
risk increase associated with a human-like DMPA dose in macaques. Other research efforts, 
such as the planned randomized clinical trial on DMPA use and HIV acquisition risk, as well 
as thorough investigations of potential alternatives to DMPA (e.g., the injectable 
contraceptive drug Net-en 6), will help identify the safest contraceptive choices for women 
with regards to HIV acquisition risk.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A: Kaplan Meier survival analyses showing the number of macaques remaining uninfected 
after vaginal SHIV challenges in the presence or absence of DMPA. Eight DMPA treated 
macaques required a median 5.5 challenges, while four real time controls and seven 
historical controls required a median 9. The difference was not statistically significant 
different (p=0.18, log-rank test). Five controls and one DMPA-treated macaque remained 
uninfected. B: Bar graphs show different outcomes for control (grey) or DMPA-treated 
(black) macaques. Analyses were performed for the number of animals infected or 
uninfected per group. P values refer to Fisher's exact test (two-tailed).
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Course of SHIV infection in controls or DMPA-treated macaques. A, B: Figures show 
plasma viremia (RNA copies/mL, determined by in-house real-time PCR assay) in both 
SHIV-infected control or DMPA-treated macaques. DMPA treatment was continued after 
infection. Three macaques remained uninfected (B0499, PHQ1, BB0540). The detection 
limit was 49 copies/mL. Viremia was aligned at peak. C: Comparison of peak viremia in 
infected animals. The black line represents median values. The difference in distribution of 
peak values was not statistically significant (p=0.94, Mann-Whitney U test). D: Mean 
viremia is shown of infected animals, including data from four infected historic controls.
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Menstrual cycles of the twelve study animals. Results of plasma progesterone measurements 
(black lines) and visual observations of sex skin swellings (grey bars) are shown, relative to 
the administration of DMPA (♀), SHIV exposure (x symbol), and first detection of infection 
(* asterisks). A: DMPA treatment abrogated cycling in all animals. B. All controls macaques 
had menstrual cycles during virus exposures.
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A: DMPA treatment led to detectable MPA levels in all treated animals. MPA levels in 
plasma are shown (right y-axis), as are endogenous progesterone levels (left y-axis). DMPA 
was injected on days 0, 28, 56, and 84. B. MPA levels are shown over time. MPA increased 
in all treated animals.
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DMPA treatment thins the vaginal epithelium. A: Top left: Untreated control animal 
BB0540 illustrating superficial non-nucleated, and underlying nucleated vaginal epithelial 
layers, and stroma. Top right: Automated measurements of non-nucleated and nucleated 
layer thicknesses by image analysis software after manual delineation of epithelial layers. 
Bottom: Loss of superficial non-nucleated layer and marked thinning of nucleated layers in 
DMPA-treated, infected (left) and uninfected (right) animals. B: Quantitative analysis of the 
vaginal epithelial measurements indicating significant epithelial thinning and loss of non-
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nucleated cell layers in DMPA-treated animals. Data are from combined measurements of 
the three biopsy sites. Thickness of the epithelium (sum of nucleated and non-nucleated 
layers) was analyzed. Mean values and standard deviations are shown, the p-value refers to 
the Satterthwaite t-test for unequal variances.
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